Centenial Surgical Suture Ltd has submitted its mandatory compliance certificate under SEBI (Depositories and Participants) Regulations 2018 for the quarter ended March 31, 2026. The filing demonstrates the company's adherence to regulatory requirements governing dematerialisation processes and depositories operations.

Regulatory Compliance Filing

The compliance certificate was filed with BSE Limited on April 16, 2026, under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations 2018. Company Secretary and Compliance Officer Mahima Bathwal, bearing membership number ACS A35069, signed and submitted the documentation to the exchange.

Registrar and Transfer Agent Confirmation

Purva Sharegistry (I) Private Limited, serving as the company's registrar and transfer agent, issued the compliance certificate on April 01, 2026. The Mumbai-based firm holds SEBI registration number INR000001112 and operates as a Category 1 registrar for IPOs and share transfer services.

Ms. Deepali Gaonkar, Compliance Officer at Purva Sharegistry, confirmed that all securities received from depository participants for dematerialisation during the quarter were properly processed. The certificate validates that:

• All securities received for dematerialisation were confirmed or rejected to depositories within prescribed timelines
• Security certificates were mutilated and cancelled after due verification by depository participants
• Depository names were substituted in the member register as registered owners
• Securities are listed on stock exchanges where previously issued securities are traded

Corporate Information

Centenial Surgical Suture Ltd operates from its registered office at F-29, MIDC, Murbad, Thane 421401, Maharashtra. The company holds multiple international certifications including ISO 9001:2015, ISO 13485:2016, ISO 14001:2015, ISO 45001:2018, WHO GMP, and CE certification, reflecting its commitment to quality standards in surgical suture manufacturing.

Compliance Framework

The SEBI Regulation 74(5) requires companies to ensure proper handling of dematerialisation requests and maintain accurate records of share transfers. This quarterly compliance certificate serves as a regulatory safeguard, confirming that the company and its registrar have followed prescribed procedures for converting physical share certificates into electronic form and updating ownership records accordingly.

Centenial Surgical Suture Ltd has formally responded to a BSE surveillance inquiry regarding unusual price movements in its shares, alleging systematic manipulation by unknown parties through coordinated trading activities.

BSE Surveillance Inquiry Response

The company received correspondence L/SURV/ONL/PV/APJ/ 2025-2026 / 3430 dated Friday, March 13, 2026, from BSE Limited's surveillance department seeking clarification on significant price movements. Company Secretary Mahima Bathwal responded on March 17, 2026, acknowledging the unusual trading patterns and providing detailed analysis of suspected manipulative activities.

Alleged Manipulation Pattern

The company identified suspicious trading characteristics that suggest coordinated price manipulation:

• Small lot transactions: Most buyers purchasing only 1-5 shares
• Geographical spread: Buyers distributed across India to avoid surveillance detection
• Repeated investors: Same individuals appearing in multiple transactions
• Synchronized trading: Coordinated buying and selling activities
• Circuit manipulation: Use of upper/lower circuit mechanisms to control price movements

The company emphasized that these transactions appear unnatural and highly suspicious, lacking genuine commercial substance.

Trading Data Analysis

Centenial Surgical Suture provided comprehensive trading data spanning multiple periods from January 2026 to March 2026, documenting extensive buy and sell activities:

Sample Trading Activity (January 2-9, 2026)

The annexures detail hundreds of individual transactions involving resident individuals, with most transactions involving minimal share quantities that would not typically justify significant price movements.

Company's Position

The management clarified several key points in their response:

• No material announcements: The company confirmed no pending announcements or material information that could justify price movements
• No regulatory proceedings: No ongoing legal or regulatory matters affecting the business
• Clean management: Company, promoters, directors, and associates have no involvement in the alleged manipulation
• Compliance commitment: Continued adherence to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Investigation Request

Centenial Surgical Suture formally requested BSE to:

• Conduct comprehensive investigation into the trading patterns
• Examine the genuineness of transactions between parties
• Initiate appropriate penal actions against involved broking houses and clients
• Treat the matter as an emergency to protect shareholder interests

The company expressed willingness to provide full assistance in any detailed investigation for probable violation of securities laws.

Market Impact Concerns

The alleged manipulation has created artificial price volatility without any fundamental business justification. The company noted that trading volumes during manipulation periods were extremely thin, lacking credentials to justify sharp price movements. This artificial activity potentially misleads genuine investors and affects the company's market reputation.

The response demonstrates the company's proactive approach to protecting shareholder interests and maintaining market integrity by reporting suspected manipulation to regulatory authorities.